The translational relevance of preclinical findings hinges on their ability to predict clinical outcomes, particularly in the context of targeted therapies. This study evaluates the in vivo efficacy of picropodophyllin (PPP) in human colorectal carcinoma xenograft models and assesses the predictive value of TP53 mutation status as a biomarker for treatment response. Subcutaneous tumors were established in athymic nude mice using TP53 wild-type HCT-8 and TP53-mutated CACO-2 cell lines. Once tumors reached an average volume of 150–200 mm³, mice were randomized into two groups: one received oral PPP at 50 mg/kg twice weekly, while the control group received saline. Tumor growth was monitored every three days using caliper measurements, and after three weeks of treatment, animals were sacrificed for necropsy. Results showed that PPP treatment significantly inhibited tumor growth in the HCT-8 group, with mean tumor volumes reduced by over 60% compared to controls (p < 0.01). In contrast, no significant difference in tumor size was observed between PPP-treated and saline-treated mice bearing CACO-2 xenografts. Histological analysis revealed extensive apoptosis and reduced proliferation markers (Ki-67) in PPP-treated wild-type tumors, but minimal changes in mutant xenografts. Western blotting of excised tumor tissues confirmed suppression of IGF-1R, AKT, and ERK phosphorylation only in the TP53 wild-type group. Notably, p-ERK levels remained elevated in CACO-2 tumors despite PPP administration, consistent with the in vitro findings.Centhaquin Technical Information These results demonstrate that PPP exerts potent antitumor activity in TP53 wild-type colorectal carcinomas in vivo, but fails to elicit a therapeutic response in TP53-mutated counterparts.Halofuginone supplier The strong correlation between TP53 genotype and treatment outcome underscores its potential as a predictive biomarker.PMID:34791799 Clinical implications are significant: patients with TP53-mutant colorectal carcinomas are unlikely to benefit from PPP monotherapy, suggesting the need for stratification in future trials. Furthermore, these data support the integration of TP53 genotyping into clinical decision-making for IGF-1R-targeted therapies. Future studies should explore combination regimens—such as PPP plus MEK or PI3K inhibitors—to overcome resistance in TP53-mutated cases. Ultimately, this work provides robust evidence that TP53 status is not only a determinant of intrinsic resistance but also a clinically actionable biomarker capable of guiding patient selection and improving therapeutic precision in colorectal cancer.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com